SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webc ...

Company Performance - Amgen's stock closed at $294.76, reflecting a -1.17% change from the previous day, underperforming the S&P 500's daily loss of 0.01% [1] - Over the last month, Amgen's shares increased by 2.98%, outperforming the Medical sector's loss of 1.59% but lagging behind the S&P 500's gain of 5.37% [1] Upcoming Earnings Report - Amgen is set to release its earnings on August 5, 2025, with an expected EPS of $5.22, representing a 5.03% increase from the prior-year quarter [2] - The Zacks Consensus Estimate for revenue is projected at $8.86 billion, up 5.64% from the year-ago period [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of $20.84 per share and revenue of $35.23 billion, indicating increases of +5.04% and +5.41% respectively from the last year [3] - Recent analyst estimate revisions suggest a positive outlook for Amgen's business operations and profit generation capabilities [3] Valuation Metrics - Amgen is currently trading at a Forward P/E ratio of 14.31, which is below the industry average Forward P/E of 18.7, indicating a discount relative to its peers [6] - The company has a PEG ratio of 2.7, compared to the industry average PEG ratio of 1.48, suggesting that Amgen's anticipated earnings growth is factored into its valuation [7] Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Amgen, has a Zacks Industry Rank of 82, placing it in the top 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Overview - Zymeworks Inc. (ZYME) shares increased by 7.1% in the last trading session, closing at $14.48, with trading volume significantly higher than usual [1] - The stock has also gained 7.1% over the past four weeks [1] Stock Performance Drivers - The rise in stock price is linked to positive investor sentiment regarding Zymeworks' early-stage pipeline candidates, ZW171 and ZW191, aimed at treating advanced mesothelin-expressing cancers and advanced solid tumors [2] Financial Expectations - The company is projected to report a quarterly loss of $0.52 per share, reflecting a year-over-year change of -100% [3] - Expected revenues are $13.66 million, which is a 29% decrease from the same quarter last year [3] Earnings Estimate Trends - The consensus EPS estimate for Zymeworks has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - Monitoring ZYME is advised to determine if the recent stock price increase can lead to further strength [4] Industry Context - Zymeworks holds a Zacks Rank of 2 (Buy) within the Zacks Medical - Biomedical and Genetics industry [5] - Another company in the same industry, Cytokinetics (CYTK), closed 0.5% higher at $38.89, with an 18.2% return over the past month [5]

Company Overview - Legend Biotech Corporation's shares increased by 6% to close at $42.13, with a notable trading volume compared to normal sessions, and a total gain of 13.9% over the past four weeks [1][2] Product Performance - The rise in stock price is attributed to investor optimism regarding the strong sales of Carvykti, a therapy for relapsed or refractory multiple myeloma, developed in partnership with Johnson & Johnson [2] Financial Expectations - The company is projected to report a quarterly loss of $0.18 per share, reflecting a year-over-year decline of 260%, while revenues are expected to reach $233.67 million, marking a 25.3% increase from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 4.1% higher in the last 30 days, indicating a potential for price appreciation [4] Industry Context - Legend Biotech is categorized within the Zacks Medical - Biomedical and Genetics industry, where Vanda Pharmaceuticals, another company in the same sector, has also shown a 1% increase in its stock price recently [4] - Vanda's consensus EPS estimate remains unchanged at -$0.34, representing a 325% decline from the previous year [5]

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $5.52, with a +2.41% increase from the previous day, outperforming the S&P 500's gain of 0.54% [1] - The stock has risen by 5.48% over the past month, contrasting with the Medical sector's decline of 2.12% and the S&P 500's increase of 4.2% [1] Upcoming Earnings - Recursion Pharmaceuticals is expected to report earnings of -$0.34 per share, indicating a year-over-year growth of 15% [2] - The projected revenue for the upcoming earnings disclosure is $15.58 million, reflecting an 8.02% increase from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at -$1.34 per share, with revenue expected to reach $73.39 million, representing increases of +20.71% and +24.73% respectively from the prior year [3] - Changes in analyst estimates for Recursion Pharmaceuticals are noted to correlate with near-term stock prices, indicating analyst optimism regarding business and profitability [3] Zacks Rank and Industry Performance - Recursion Pharmaceuticals currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate remaining unchanged over the last 30 days [5] - The Medical - Biomedical and Genetics industry ranks in the top 34% of all industries, with a Zacks Industry Rank of 83, suggesting that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [6]

Company Performance - Viking Therapeutics, Inc. (VKTX) experienced a daily increase of +1.39% to $32.07, outperforming the S&P 500's gain of 0.54% [1] - Prior to the latest trading session, the company's shares had risen by 20.36%, contrasting with the Medical sector's decline of 2.12% and the S&P 500's increase of 4.2% [1] Earnings Forecast - The upcoming earnings release is anticipated to show an EPS of -$0.44, reflecting a 120% decline compared to the same quarter last year [2] - For the full year, the Zacks Consensus Estimates predict an EPS of -$1.86 and revenue of $25 million, indicating changes of -84.16% and 0% respectively from the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics should be monitored, as they often indicate short-term business trends [3] - Positive estimate revisions are viewed as a sign of optimism regarding the business outlook [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with 1 stocks averaging an annual return of +25% since 1988 [5] - Currently, Viking Therapeutics holds a Zacks Rank of 3 (Hold), with no changes in the consensus EPS projection over the past 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry, which includes Viking Therapeutics, ranks in the top 34% of over 250 industries according to the Zacks Industry Rank [6] - The Zacks Industry Rank measures the strength of individual industry groups based on the average Zacks Rank of stocks within those groups [6]

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Amgen (AMGN) , which belongs to the Zacks Medical - Biomedical and Genetics industry.This world's largest biotech drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 11.68%.For the last reported quarter, Amgen came out with earnings of $4.9 per ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Harmony Biosciences Holdings, Inc. (HRMY) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 23.53%.For the most recent qu ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is BrightSpring Health Services, Inc. (BTSG) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.BrightSpring Health Services, Inc. is one of 986 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $9.60, demonstrating a +1.8% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.32% for the day. On the other hand, the Dow registered a gain of 0.53%, and the technology-centric Nasdaq increased by 0.26%. Shares of the company have appreciated by 10.29% over the course of the past month, outperforming the Medical sector's loss of 3.4%, and the S&P 500's gain of 4.51%.Market part ...